Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Glucose Levels Affect Total Joint Replacement Outcomes in Patients With Diabetes - (DGNews)
    Endocrine Society Responds to Insulin Glargine Studies With Recommendations - (DGNews)
    TopAbstracts in Diabetes 06/30/2009 - (DGNews)
    Certain Biomarkers Have Limitations in Predicting Cardiovascular Events - (DGNews)
    Glucose Challenge Test Is Accurate for Diabetes, Prediabetes Screening - (DGNews)

    News archive

     Recent webcasts/CME - Diabetes
    • Matching Treatment to Need in Type 2 Diabetes: Using Incretin-Based Oral Therapies Across the Clinical Spectrum
    • Achieving Glycemic Control After Standard Therapy Has Failed
    • The Challenge of Type 2 Diabetes: Emerging Options for Improving Glycemic Control
      Addressing Patient Challenges to Diabetes Treatment Through the Use of Incretin-based Therapies
      Management of Hyperglycemia in Acute-Care Settings and the Transition to Ambulatory Care

      Webcasts/CME archive

       Recent cases - Diabetes
        Improvement of the Diabetic Foot Upon Testosterone Administration to Hypogonadal Men with Peripheral Arterial Disease. Report of Three Cases
        Caudal Regression Syndrome and Popliteal Webbing in Connection with Maternal Diabetes Mellitus: A Case Report and Literature Review
        Atypical Onset of Diabetes in a Teenage Girl: A Case Report
        Painful Swelling in the Thigh: Diabetic Muscle Infarction
        Atypical Ketosis-Prone Diabetes

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Research Affirms the Benefits of Combination of Chromium Picolinate and Biotin for Improving Blood Sugar in People with Type 2 Diabetes

        Additional Research Presented at the 19th World Diabetes Congress Meeting Supports the Efficacy and Safety of Chromium Picolinate in Diabetes Management

        PURCHASE, NY -- January 8, 2007 -- Nutrition 21, Inc. (NASDAQ: NXXI) today announced the results of a recent placebo controlled, double-blind, randomized, single center study that demonstrated that Diachrome®, a patented combination of chromium picolinate and biotin, safely improves blood glucose levels and cholesterol metabolism in people with type 2 diabetes.

        Published in the December issue of Diabetes Technology and Therapeutics, the study supports the role of chromium picolinate – the most studied, highly absorbed and efficacious form of chromium – plus biotin as a safe and effective nutritional adjunct therapy in diabetes care.

        The 30-day study examined 36 overweight or obese poorly controlled patients with type 2 diabetes taking Diachrome who were already receiving oral anti-diabetic drug(s). The results also showed a significantly greater reduction in the total area under the curve for glucose (AUCg) during the oral glucose tolerance test (OGTT) for the treatment group (mean change -9.7%) compared with the placebo group (mean change +5.1%).

        Mean fructosamine levels, a measure of the average blood glucose level during a period of three weeks, were also significantly reduced in the treatment group (-1.3 mmol/L) compared to the placebo group (0.7 mmol/L).

        "Results from this pilot study promote the potential benefits of supplementing chromium picolinate and biotin with one's daily diabetes care regimen," said Gregory Singer, MD, lead author and cardiovascular medicine specialist at Yale University School of Medicine. "Chromium picolinate with biotin represents an adjunctive strategy to conventional oral diabetes therapy for improved blood sugar control and cholesterol metabolism."

        A larger 400 patient, 90-day randomized placebo controlled study to determine the effects of chromium picolinate/biotin on hemoglobin A1c and other risk factors in type 2 diabetes is expected to be published next year.

        "Previous studies have demonstrated that chromium picolinate can significantly impact A1c and other critical markers in people with type 2 diabetes," said Dr. Singer. "Additional research currently underway may provide us with further understanding of the supplement's role in the management of type 2 diabetes."

        Another study released this month at the 19th World Diabetes Congress meeting in Cape Town, South Africa, demonstrated that supplementing with chromium picolinate, an active ingredient in Diachrome, led to significant improvements in blood sugar levels of people with type 2 diabetes over a six-year period. In addition to existing treatments, 1,056 patients with diabetes ages 20 to 90 years old were observed among nine sites before and during supplementation with 500 mcg daily of chromium as chromium picolinate for one to six years.

        A significant decrease in fasting glucose levels of 4.67 mmol/L and postprandial glucose levels of 5.77 mmol/L was seen in patients taking chromium picolinate. The study showed that blood glucose levels continued to improve each year throughout the six years of the study.

        "This study – one of the largest and longest clinical trials measuring chromium picolinate's effects on blood glucose levels – underscores the nutrition supplement's beneficial role in helping manage type 2 diabetes," said lead investigator Nancy Cheng, MD, PhD, Senior Director of Tang-An Diabetic Clinic and Education Center in Beijing.

        Chromax® chromium picolinate, found in Diachrome and used in these studies, has been recognized as safe by many of the world's leading government and academic research institutions, including the U.S. Food & Drug Administration, the Institute of Medicine and the UK's Food Standards Agency. In addition, biotin has been deemed safe by the Food and Drug Administration and is also Generally Recognized as Safe (GRAS) for use in foods and supplements.

        About Diachrome
        Diachrome is a non-prescription nutrient-based therapy formulated to help support blood glucose management in people with diabetes. It is composed of two safe and beneficial nutrients: chromium (as Chromax® chromium picolinate) and biotin (a B-vitamin). A growing body of scientific evidence indicates that Diachrome's unique ingredient combination has positive effects on insulin function, blood glucose, lipid metabolism and cardiovascular health. The nutritional therapy can be found in retail stores nationwide.


        SOURCE: Nutrition 21



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send